Renaissance Technologies
ACXP icon

Renaissance Technologies’s Acurx Pharmaceuticals ACXP Stock Holding History

Renaissance Technologies’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,389
Closed -$44.8K – 3463
2025
Q2 		$44.8K Buy
4,389
+3,059
+230% +$24.6K ﹤0.01% 3408
2025
Q1 		$10.4K Buy
1,330
+596
+81% +$8.03K ﹤0.01% 3392
2024
Q4 		$11.9K Buy
+734
New +$22.1K ﹤0.01% 3512
2023
Q4 		– Sell
-940
Closed -$28K – 3693
2023
Q3 		$28K Buy
+940
New +$36K ﹤0.01% 3480

Other funds holding ACXP

PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.33B AUM 24% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return
GWSG
GPS Wealth Strategies Group Centennial, Colorado $117M AUM 24.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Renaissance Technologies's ACXP Position: Q3 2025 in Review

Renaissance Technologies sold out of Acurx Pharmaceuticals (ACXP) in Q3 2025, closing a stake of 4,389 shares — an estimated $44.8K sold.

Renaissance Technologies first reported a position in ACXP in Q3 2023 and held it in 4 quarters. The position peaked at $44.8K in Q2 2025. 16 funds tracked by Wall St. Rank hold ACXP as of Q3 2025.

  • Renaissance Technologies reported no remaining Acurx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Renaissance Technologies sold 4,389 Acurx Pharmaceuticals shares in Q3 2025, an estimated $44.8K.
  • Renaissance Technologies first reported a position in Acurx Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • Renaissance Technologies's Acurx Pharmaceuticals position peaked at $44.8K in Q2 2025.
  • 16 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.